Asia
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.
Takeda Pharmaceutical and Ovid Therapeutics announced on Tuesday that they have gathered positive data from their Phase II ELEKTRA study of soticlestat in children with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS).
The U.S. Department of Justice charged the Israel-based company with three counts of fixing prices to reap more than $350 million from customers through the scheme.
A novel prodrug to combat high-risk pediatric solid tumors is being developed by PEEL Therapeutics, Inc.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
The genetic sequences of the two samples were markedly different, which strengthened the theory that the patient had been infected a second time.
This morning, Osaka, Japan-based Takeda officially announced the sale of TCHC to the investment firm.
There are several China-based companies that have vaccine candidates in Phase III.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 24, 2020.
PRESS RELEASES